Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.64 |
| ▸ | MDM4 | O15151 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.53 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL378040 | 1.00 | CASP3 (0.64) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL29367388 | 1.00 | CASP3 (0.64) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL1486199 | 1.00 | CASP3 (0.64) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL30055375 | 1.00 | CASP3 (0.64) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL29352428 | 1.00 | CASP3 (0.64) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL30988976 | 0.93 | CASP3 (0.56) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL29401049 | 0.92 | CASP3 (0.60) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL29047043 | 0.91 | CASP3 (0.59) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL30656568 | 0.91 | MDM4 (0.59) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL29053258 | 0.91 | CASP3 (0.58) | CASP3MDM4TP53KMT2AMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112430588-B | Short peptide for resisting novel coronavirus infection and preparation method and application thereof | 中国人民解放军陆军军医大学 | 2022-12-30 | — | — | CN | claimed |
| CN-109701013-B | Targeted nano drug delivery system and preparation method thereof | 安徽工程大学 | 2021-07-13 | — | — | CN | claimed |
| CN-112430588-A | Short peptide for resisting novel coronavirus infection and preparation method and application thereof | 中国人民解放军陆军军医大学 | 2021-03-02 | — | — | CN | claimed |
| CN-109701013-A | A kind of targeted nanometer drug delivery system and preparation method | 安徽工程大学 | 2019-05-03 | — | — | CN | claimed |
| EP-3473249-A1 | CROSSLINKABLE DENDRIMERS | Wayne State University (US) | 2019-04-24 | — | — | EP | claimed |
| CN-102643330-B | A kind of synthetic method and its medical application of bone target medicine Aspartate hexapeptide Danshensu | 广东医科大学 | 2018-10-19 | — | — | CN | claimed |
| CN-107865289-A | A kind of chitosan antiseptics for natural food and preparation method thereof | 成都新柯力化工科技有限公司 | 2018-04-03 | — | — | CN | claimed |
| CN-104586752-B | A kind of glucose-sensitive self-discipline formula insulin releasing microgel carrier and preparation method thereof | 湖北大学 | 2017-09-01 | — | — | CN | claimed |
| US-20170028075-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | Ashvattha Therapeutics, Inc. | 2017-02-02 | — | — | US | claimed |
| US-9526794-B2 | Injectable dendrimer hydrogel nanoparticles | WAYNE STATE UNIVERSITY (US) | 2016-12-27 | — | — | US | claimed |
| CN-105585613-A | Eptifibatide synthesis method | HE RUNZE | 2016-05-18 | — | — | CN | claimed |
| US-20130136697-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | NATIONAL INSTITUTES OF HEALTH (US) | 2013-05-30 | — | — | US | claimed |
| EP-2552458-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | Wayne State University (US) | 2013-02-06 | — | — | EP | claimed |
| CN-102643330-A | Synthetic method for aspartate hexapeptide danshensu as bone targeted drug and medical application of aspartate hexapeptide danshensu | GUANGDONG MEDICAL COLLEGE | 2012-08-22 | — | — | CN | claimed |
| WO-2011123591-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | WAYNE STATE UNIVERSITY (US) | 2011-10-06 | — | — | WO | claimed |
| CN-100590068-C | Method for preparing primary amine carbon nano tube | UNIV TONGJI | 2010-02-17 | — | — | CN | claimed |
| CN-101177259-A | Method for preparing primary amine carbon nano tube | UNIV TONGJI (CN) | 2008-05-14 | — | — | CN | claimed |
| CN-1202131-C | Technology of one kettle method for liquid phase synthesizing thymopentapeptide | UNIV JILIN (CN) | 2005-05-18 | — | — | CN | claimed |
| CN-1442428-A | Technology of one kettle method for liquid phase synthesizing thymopentapeptide | UNIV JILIN (CN) | 2003-09-17 | — | — | CN | claimed |
| CN-121537485-A | Cyclohexapeptide and preparation method and application thereof | 未来多肽生物科技(烟台)有限公司 | 2026-02-17 | — | — | CN | disclosed |
| CN-120248044-A | Cyclohexapeptide and preparation method and application thereof | 陕西未来多肽生物科技有限公司 | 2025-07-04 | — | — | CN | disclosed |
| CN-119591674-A | Cyclohexapeptide and preparation method and application thereof | 陕西未来多肽生物科技有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-118184532-A | Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound containing the amino acid, and process for producing the same | 中外制药株式会社 | 2024-06-14 | — | — | CN | disclosed |
| CN-118146313-A | Self-assembled short peptide and application thereof in hemostasis and injury repair | 成都赛恩贝外科学研究院 | 2024-06-07 | — | — | CN | disclosed |
| WO-2024101402-A1 | PHARMACEUTICAL COMPOSITION CONTAINING CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT AGAINST HRAS AND NRAS | 中外製薬株式会社 | 2024-05-16 | — | — | WO | disclosed |
| US-11958878-B2 | Therapeutic agent for glycogen storage disease type IA | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-04-16 | — | — | US | disclosed |
| CN-113454058-B | Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound containing the amino acid, and process for producing the same | 中外制药株式会社 | 2024-03-22 | — | — | CN | disclosed |
| CN-117500819-A | Lipid and composition | 相互药工株式会社 | 2024-02-02 | — | — | CN | disclosed |
| CN-117043679-A | Composition for forming resist underlayer film having protected alkaline organic group | 日产化学株式会社 | 2023-11-10 | — | — | CN | disclosed |
| CN-116970042-A | Antiviral polypeptide analogues | 上海多米瑞生物技术有限公司 | 2023-10-31 | — | — | CN | disclosed |
| EP-4234537-A1 | REAGENT FOR MEASURING SKIN SENSITIZATION, COMPOUND, AND METHOD FOR MEASURING SKIN SENSITIZATION | FUJIFILM Corporation (JP) | 2023-08-30 | — | — | EP | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| CN-114989249-B | Nano short peptide R-LIFE-1 and application thereof in medicines, medical cosmetology and biomedicine | 成都赛恩贝外科学研究院 | 2023-07-21 | — | — | CN | disclosed |
| US-11623009-B2 | Bone fracture repair by targeting of agents that promote bone healing | PURDUE RESEARCH FOUNDATION (US) | 2023-04-11 | — | — | US | disclosed |
| CN-115677829-A | Glycosylation target FAP compound, target FAP labeling complex, preparation method and application thereof | 广州华复生物科技有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-112430588-B | Short peptide for resisting novel coronavirus infection and preparation method and application thereof | 中国人民解放军陆军军医大学 | 2022-12-30 | — | — | CN | disclosed |
| US-11446238-B2 | Injectable dendrimer hydrogel nanoparticles | WAYNE STATE UNIVERSITY (US) | 2022-09-20 | — | — | US | disclosed |
| CN-115057912-A | Method for preparing procatide | 哈药集团生物工程有限公司 | 2022-09-16 | — | — | CN | disclosed |
| CN-114989249-A | Nano short peptide R-LIFE-1 and application thereof in medicines, medical cosmetology and biomedicine | 成都赛恩贝外科学研究院 | 2022-09-02 | — | — | CN | disclosed |
| CN-114437714-A | Circular polarization luminescent material based on enantioselective co-assembly and application thereof | 中国科学院化学研究所 | 2022-05-06 | — | — | CN | disclosed |
| CN-114181284-A | Application of nano short peptide DRF3 in medicines, NK cell carriers and biomedicine | 成都赛恩贝外科学研究院 | 2022-03-15 | — | — | CN | disclosed |
| CN-113943259-A | Amino acid derivative, preparation method and application thereof | 西安禾渼生物医药有限公司 | 2022-01-18 | — | — | CN | disclosed |
| CN-113692401-A | Process for producing aromatic amino acid derivative | 中外制药株式会社 | 2021-11-23 | — | — | CN | disclosed |
| CN-113454058-A | Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound comprising the same, and method for producing the same | 中外制药株式会社 | 2021-09-28 | — | — | CN | disclosed |
| US-11059789-B2 | Isoquinoline-steroid conjugates and uses thereof | AERIE PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| CN-109701013-B | Targeted nano drug delivery system and preparation method thereof | 安徽工程大学 | 2021-07-13 | — | — | CN | disclosed |
| EP-3810627-A1 | SYNTHETIC METHOD OF BIVALIRUNDIN | Shanghai Space Peptides Pharmaceutical Co., Ltd. (CN) | 2021-04-28 | — | — | EP | disclosed |
| CN-112638386-A | Isoquinoline-steroid conjugates and uses thereof | 爱瑞制药公司 | 2021-04-09 | — | — | CN | disclosed |
| CN-112430588-A | Short peptide for resisting novel coronavirus infection and preparation method and application thereof | 中国人民解放军陆军军医大学 | 2021-03-02 | — | — | CN | disclosed |
| CN-112424216-A | Synthetic method of bivalirudin | 上海胜泽泰医药科技有限公司 | 2021-02-26 | — | — | CN | disclosed |
| EP-3763815-A1 | THERAPEUTIC AGENT FOR GLYCOGEN STORAGE DISEASE TYPE IA | Daiichi Sankyo Company, Limited (JP) | 2021-01-13 | — | — | EP | disclosed |
| US-20210000962-A1 | BONE FRACTURE REPAIR BY TARGETING OF AGENTS THAT PROMOTE BONE HEALING | UNIVERSITY OF UTAH | 2021-01-07 | — | — | US | disclosed |
| US-20200407394-A1 | THERAPEUTIC AGENT FOR GLYCOGEN STORAGE DISEASE TYPE IA | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-12-31 | — | — | US | disclosed |
| US-10744203-B2 | Bone fracture repair by targeting of agents that promote bone healing | PURDUE RESEARCH FOUNDATION (US) | 2020-08-18 | — | — | US | disclosed |
| CN-111356456-A | 2-arylsulfonamido-iV-arylacetamide derived Stat3 inhibitor | 夏威夷大学 | 2020-06-30 | — | — | CN | disclosed |
| US-20200071275-A1 | ISOQUINOLINE-STEROID CONJUGATES AND USES THEREOF | ALCON INC. (CH) | 2020-03-05 | — | — | US | disclosed |
| WO-2019241903-A1 | SYNTHETIC METHOD OF BIVALIRUNDIN | SHANGHAI SPACE PEPTIDES PHARMACEUTICAL CO., LTD. (CN) | 2019-12-26 | — | — | WO | disclosed |
| CN-105582014-B | Compositions and methods for treating leukemia | 达那-法伯癌症研究所 | 2019-06-14 | — | — | CN | disclosed |
| US-20190160172-A1 | BONE FRACTURE REPAIR BY TARGETING OF AGENTS THAT PROMOTE BONE HEALING | PURDUE RESEARCH FOUNDATION (US) | 2019-05-30 | — | — | US | disclosed |
| US-10279044-B2 | Bone fracture repair by targeting of agents that promote bone healing | PURDUE RESEARCH FOUNDATION (US) | 2019-05-07 | — | — | US | disclosed |
| CN-109701013-A | A kind of targeted nanometer drug delivery system and preparation method | 安徽工程大学 | 2019-05-03 | — | — | CN | disclosed |
| EP-3473249-A1 | CROSSLINKABLE DENDRIMERS | Wayne State University (US) | 2019-04-24 | — | — | EP | disclosed |
| CN-102643330-B | A kind of synthetic method and its medical application of bone target medicine Aspartate hexapeptide Danshensu | 广东医科大学 | 2018-10-19 | — | — | CN | disclosed |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | COLD SPRING HARBOR LABORATORY | 2018-08-09 | — | — | US | disclosed |
| US-20180147286-A1 | BONE FRACTURE REPAIR BY TARGETING OF AGENTS THAT PROMOTE BONE HEALING | UNIVERSITY OF UTAH | 2018-05-31 | — | — | US | disclosed |
| US-9951324-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2018-04-24 | — | — | US | disclosed |
| CN-107865289-A | A kind of chitosan antiseptics for natural food and preparation method thereof | 成都新柯力化工科技有限公司 | 2018-04-03 | — | — | CN | disclosed |
| CN-104586752-B | A kind of glucose-sensitive self-discipline formula insulin releasing microgel carrier and preparation method thereof | 湖北大学 | 2017-09-01 | — | — | CN | disclosed |
| CN-104311562-B | For treating neoplasia, inflammatory disease and the composition and method of other imbalances | 达那-法伯癌症研究所 | 2017-07-04 | — | — | CN | disclosed |
| CN-103180318-B | male contraceptive compositions and methods of use | 达那-法伯癌症研究所 | 2017-05-10 | — | — | CN | disclosed |
| US-9586916-B2 | Integrin antagonist conjugates for targeted delivery to cells expressing alpha-V-beta-3 | HOFFMANN-LA ROCHE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| CN-106456653-A | Treatment of conditions associated with hyperinsulinaemia | 腾沙治疗公司 | 2017-02-22 | — | — | CN | disclosed |
| US-20170028075-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | Ashvattha Therapeutics, Inc. | 2017-02-02 | — | — | US | disclosed |
| US-9526794-B2 | Injectable dendrimer hydrogel nanoparticles | WAYNE STATE UNIVERSITY (US) | 2016-12-27 | — | — | US | disclosed |
| WO-2016196400-A1 | BONE FRACTURE REPAIR BY TARGETING OF AGENTS THAT PROMOTE BONE HEALING | PURDUE RESEARCH FOUNDATION (US) | 2016-12-08 | — | — | WO | disclosed |
| CN-106163559-A | anti-HER 3 antibody-drug conjugates | 第三共株式会社 | 2016-11-23 | — | — | CN | disclosed |
| US-20160151508-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2016-06-02 | — | — | US | disclosed |
| CN-103119160-B | For regulating compositions and the method for metabolism | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-06-01 | — | — | CN | disclosed |
| CN-105582014-A | Compositions and methods for treating leukemia | DANA FARBER CANCER INST INC | 2016-05-18 | — | — | CN | disclosed |
| CN-105585613-A | Eptifibatide synthesis method | HE RUNZE | 2016-05-18 | — | — | CN | disclosed |
| US-9320741-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-9257576-B2 | Amino acid generator and polysiloxane composition containing the same | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-02-09 | — | — | US | disclosed |
| CN-105189514-A | Pyrrolo- and pyrazolo-triazolodiazepines as bet-protein inhibitors for treating hyperproliferative diseases | Bayer Pharma AG | 2015-12-23 | — | — | CN | disclosed |
| CN-105164135-A | 4-substituted pyrrolo- and pyrazolo-diazepines | Bayer Pharma AG | 2015-12-16 | — | — | CN | disclosed |
| CN-103154246-B | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-11-25 | — | — | CN | disclosed |
| US-20150150885-A1 | Compositions and Methods for Treating Neoplasia, Inflammatory Disease and Other Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-04 | — | — | US | disclosed |
| CN-103265629-B | Novel solid phase synthesis process for preparing thymalfasin | FUJIAN MINDONG REJUVENATION PHARMACEUTICAL CO LTD | 2015-03-18 | — | — | CN | disclosed |
| US-20150038523-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3 | HOFFMANN-LA ROCHE INC. (US) | 2015-02-05 | — | — | US | disclosed |
| CN-104311562-A | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA FARBER CANCER INST INC | 2015-01-28 | — | — | CN | disclosed |
| CN-103037865-B | Compounds for the treatment of neoplasia, inflammatory diseases and other disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-10-29 | — | — | CN | disclosed |
| CN-104010638-A | Magnetic Composition, And Method For Producing Same | IHI CORP | 2014-08-27 | — | — | CN | disclosed |
| CN-102037092-B | Amino acid generator and polysiloxane composition containing the same | NISSAN CHEMICAL IND LTD | 2014-07-02 | — | — | CN | disclosed |
| US-20130313669-A1 | AMINO ACID GENERATOR AND POLYSILOXANE COMPOSITION CONTAINING THE SAME | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-11-28 | — | — | US | disclosed |
| CN-103265629-A | Novel solid phase synthesis process for preparing thymalfasin | FUJIAN MINDONG REJUVENATION PHARMACEUTICAL CO LTD | 2013-08-28 | — | — | CN | disclosed |
| US-20130197205-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | HOFFMANN-LA ROCHE INC. (US) | 2013-08-01 | — | — | US | disclosed |
| CN-103180318-A | Male contraceptive compositions and methods of use | DANA FARBER CANCER INST INC | 2013-06-26 | — | — | CN | disclosed |
| CN-103154246-A | Compositions and methods for treating leukemia | DANA FARBER CANCER INST INC | 2013-06-12 | — | — | CN | disclosed |
| US-20130136697-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | NATIONAL INSTITUTES OF HEALTH (US) | 2013-05-30 | — | — | US | disclosed |
| CN-103119160-A | Compositions and methods for modulating metabolism | DANA FARBER CANCER INST INC | 2013-05-22 | — | — | CN | disclosed |
| CN-103037865-A | Compositions and methods for treating neoplasia, inflammatory diseases and other disorders | DANA FARBER CANCER INST INC | 2013-04-10 | — | — | CN | disclosed |
| EP-2571875-A1 | MALE CONTRACEPTIVE COMPOSITIONS AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| EP-2569434-A2 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | Dana-Farber Cancer Institute, Inc. (US) | 2013-03-20 | — | — | EP | disclosed |
| EP-2569429-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLISM | Dana-Farber Cancer Institute, Inc. (US) | 2013-03-20 | — | — | EP | disclosed |
| EP-2552458-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | Wayne State University (US) | 2013-02-06 | — | — | EP | disclosed |
| US-20120294924-A1 | Peptide-Lipid Conjugates And Uses Thereof | TICE THOMAS (US) | 2012-11-22 | — | — | US | disclosed |
| EP-2297196-B1 | VACCINE AGAINST AMYLOID FOLDING INTERMEDIATE | NEDERLANDEN STAAT (NL) | 2012-11-14 | — | — | EP | disclosed |
| CN-102643330-A | Synthetic method for aspartate hexapeptide danshensu as bone targeted drug and medical application of aspartate hexapeptide danshensu | GUANGDONG MEDICAL COLLEGE | 2012-08-22 | — | — | CN | disclosed |
| EP-2408759-A1 | PROCESSES FOR PREPARING AMINO-SUBSTITUTED GAMMA-LACTAMS | Valorisation-Recherche, Société en Commandite (CA) | 2012-01-25 | — | — | EP | disclosed |
| WO-2011143657-A1 | MALE CONTRACEPTIVE COMPOSITIONS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143660-A2 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011123591-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | WAYNE STATE UNIVERSITY (US) | 2011-10-06 | — | — | WO | disclosed |
| US-20110182928-A1 | VACCINE AGAINST AMYLOID FOLDING INTERMEDIATE | DE STAAT DER NEDERLANDEN, VERT. DOOR DE MINISTER VAN VWS (NL) | 2011-07-28 | — | — | US | disclosed |
| CN-102037092-A | Amino acid generator and polysiloxane composition containing the same | NISSAN CHEMICAL IND LTD | 2011-04-27 | — | — | CN | disclosed |
| US-20110073977-A1 | AMINO ACID GENERATOR AND POLYSILOXANE COMPOSITION CONTAINING THE SAME | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-03-31 | — | — | US | disclosed |
| EP-2297196-A1 | VACCINE AGAINST AMYLOID FOLDING INTERMEDIATE | De Staat Der Nederlanden, Vert. Door De Minister Van VWS (NL) | 2011-03-23 | — | — | EP | disclosed |
| EP-1797110-B1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | AICURIS GMBH & CO KG (DE) | 2011-01-12 | — | — | EP | disclosed |
| US-7812152-B2 | Amphiphilic cyclodextrin derivatives, method for preparation thereof and uses thereof | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-10-12 | — | — | US | disclosed |
| US-7812152-B2 | Amphiphilic cyclodextrin derivatives, method for preparation thereof and uses thereof | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-10-12 | — | — | US | disclosed |
| US-20100063013-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2010-03-11 | — | — | US | disclosed |
| CN-100590068-C | Method for preparing primary amine carbon nano tube | UNIV TONGJI | 2010-02-17 | — | — | CN | disclosed |
| WO-2010002251-A1 | VACCINE AGAINST AMYLOID FOLDING INTERMEDIATE | DE STAAT DER NEDERLANDEN, VERT. DOOR DE MINISTER VAN VWS (NL) | 2010-01-07 | — | — | WO | disclosed |
| EP-2139876-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2010-01-06 | — | — | EP | disclosed |
| US-7491707-B1 | Synthetic lipid-a-analogs and uses thereof | BIOMIRA, INC. (CA) | 2009-02-17 | — | — | US | disclosed |
| WO-2008116302-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2008-10-02 | — | — | WO | disclosed |
| CN-101177259-A | Method for preparing primary amine carbon nano tube | UNIV TONGJI (CN) | 2008-05-14 | — | — | CN | disclosed |
| EP-1814588-A2 | ANTIINFECTIVE LIPOPEPTIDES | Cubist Pharmaceuticals, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| EP-1100816-B1 | AEROTHRICIN ANALOGS, THEIR PREPARATION AND USE | BASILEA PHARMACEUTICA AG (CH) | 2007-08-08 | — | — | EP | disclosed |
| US-20070142324-A1 | Amphiphilic cyclodextrin derivatives, method for preparation thereof and uses thereof | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2007-06-21 | — | — | US | disclosed |
| WO-2006110185-A2 | ANTIINFECTIVE LIPOPEPTIDES | CUBIST PHARMACEUTICALS, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| EP-1423414-A4 | NOVEL DEPSIPEPTIDES AND PROCESS FOR PREPARING SAME | CUBIST PHARM INC (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20050137138-A1 | E2F activity-inhibiting compound | KYOWA HAKKO KOGYO CO., LTD (JP) | 2005-06-23 | — | — | US | disclosed |
| CN-1202131-C | Technology of one kettle method for liquid phase synthesizing thymopentapeptide | UNIV JILIN (CN) | 2005-05-18 | — | — | CN | disclosed |
| EP-1423414-A1 | NOVEL DEPSIPEPTIDES AND PROCESS FOR PREPARING SAME | Cubist Pharmaceuticals, Inc. (US) | 2004-06-02 | — | — | EP | disclosed |
| EP-1251827-B1 | NASALLY ADMINISTRABLE ANTIFUNGAL CYCLIC PEPTIDE COMPOSITIONS | BASILEA PHARMACEUTICA AG (CH) | 2004-05-26 | — | — | EP | disclosed |
| US-6713449-B1 | E2F activity inhibitory compounds | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-03-30 | — | — | US | disclosed |
| CN-1442428-A | Technology of one kettle method for liquid phase synthesizing thymopentapeptide | UNIV JILIN (CN) | 2003-09-17 | — | — | CN | disclosed |
| US-20030055213-A1 | Endothelin-antagonizing peptide | TANAKA TAKEO (JP) | 2003-03-20 | — | — | US | disclosed |
| WO-2003014147-A1 | NOVEL DEPSIPEPTIDES AND PROCESS FOR PREPARING SAME | CUBIST PHARMACEUTICALS, INC. (US) | 2003-02-20 | — | — | WO | disclosed |
| US-6489440-B1 | Cyclic compounds | BASILEA PHARMACEUTICA AG (CH) | 2002-12-03 | — | — | US | disclosed |
| EP-1251827-A2 | NASALLY ADMINISTRABLE CYCLIC PEPTIDE COMPOSITIONS | Basilea Pharmaceutica AG (CH) | 2002-10-30 | — | — | EP | disclosed |
| CN-1088708-C | Amidine derivatives useful as anti-platelet aggreation inhibitors and vasodilators | G S SEARLE & CO (US) | 2002-08-07 | — | — | CN | disclosed |
| US-20010038824-A1 | Intranasal cyclic peptide formulations | BASILEA PHARMACEUTICA AG (CH) | 2001-11-08 | — | — | US | disclosed |
| CN-1313846-A | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cystenine proteases | IDUN PHARMACEUTICALS INC (US) | 2001-09-19 | — | — | CN | disclosed |
| WO-2001052894-A2 | NASALLY ADMINISTRABLE CYCLIC PEPTIDE COMPOSITIONS | BASILEA PHARMACEUTICA AG (CH) | 2001-07-26 | — | — | WO | disclosed |
| EP-1100816-A1 | AEROTHRICIN ANALOGS, THEIR PREPARATION AND USE | F. HOFFMANN-LA ROCHE AG (CH) | 2001-05-23 | — | — | EP | disclosed |
| US-6194195-B1 | PURE CULTURE; FOR PRODUCTION OF HYPOTENSIVE AGENTS AND THERAPIES FOR ASTHMA, CEREBRAL APOPLEXY, ANGINA PECTORIS, ACUTE RENAL FAILURE, CARDIAC INFARCTION, AND CEREBRAL VASOSPASM | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-02-27 | — | — | US | disclosed |
| WO-2000005251-A1 | AEROTHRICIN ANALOGS, THEIR PREPARATION AND USE | F. HOFFMANN-LA ROCHE AG (CH) | 2000-02-03 | — | — | WO | disclosed |
| EP-0963999-A1 | E2F ACTIVITY INHIBITORY COMPOUNDS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1999-12-15 | — | — | EP | disclosed |
| WO-1999054321-A1 | SUBSTITUTED DIAMINES AND THEIR USE AS CELL ADHESION INHIBITORS | AVENTIS PHARMA LIMITED (GB) | 1999-10-28 | — | — | WO | disclosed |
| CN-1226898-A | Peptides promoting activation of dormant TGF-beta and method for screening compound for regulating activity of TGF-beta | KYOWA HAKKO KOGYO KK (JP) | 1999-08-25 | — | — | CN | disclosed |
| CN-1189833-A | Amidine derivatives useful as anti-platelet aggreation inhibitors and vasodilators | SEARLE & CO (US) | 1998-08-05 | — | — | CN | disclosed |
| EP-0770623-A1 | NOVEL CALCITONIN DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1997-05-02 | — | — | EP | disclosed |
| EP-0295316-B1 | Antitumor amino acid and peptide derivatives of 1,4-bis[ (aminoalkyl and hydroxyaminoalkyl)- amino]-5,8 dihydroxyanthraquinones | AMERICAN CYANAMID CO (US) | 1995-11-08 | — | — | EP | disclosed |
| EP-0679658-A1 | ENDOTHELIN-ANTAGONIZING PEPTIDE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1995-11-02 | — | — | EP | disclosed |
| EP-0496836-A4 | SYNTHESIS AND USE OF AMINO ACID FLUORIDES AS PEPTIDE COUPLING REAGENTS | — | 1993-05-05 | — | — | EP | disclosed |
| EP-0496836-A1 | SYNTHESIS AND USE OF AMINO ACID FLUORIDES AS PEPTIDE COUPLING REAGENTS. | RES CORP TECHNOLOGIES INC (US) | 1992-08-05 | — | — | EP | disclosed |
| EP-0489220-A1 | Cytotoxic N,N'-bis (succinyl-peptide-) derivatives of 1,4-bis (aminoalkyl)-5,8-dihydroxyanthraquinones and antibody conjugates thereof | AMERICAN CYANAMID COMPANY (US) | 1992-06-10 | — | — | EP | disclosed |
| US-5101059-A | Xanthene compounds | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1992-03-31 | — | — | US | disclosed |
| WO-1991008190-A1 | AMINO ACID PROTECTING GROUPS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1991-06-13 | — | — | WO | disclosed |
| WO-1991005564-A1 | SYNTHESIS AND USE OF AMINO ACID FLUORIDES AS PEPTIDE COUPLING REAGENTS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1991-05-02 | — | — | WO | disclosed |
| JP-S6475460-A | PRODUCTION OF ASPARTIC ACID DERIVATIVE AND PEPTIDE | WATANABE HIDEHIKO | 1989-03-22 | — | — | JP | disclosed |
| EP-0295316-A2 | Antitumor amino acid and peptide derivatives of 1,4-bis[ (aminoalkyl and hydroxyaminoalkyl)- amino]-5,8 dihydroxyanthraquinones | AMERICAN CYANAMID COMPANY (US) | 1988-12-21 | — | — | EP | disclosed |
| US-4732970-A | Antitumor amino acid and peptide derivatives of 1,4-bis(aminoalkyl and hydroxy-aminoalkyl)amino)-5,8-dihydroxyanthraquinones | AMERICAN CYANAMID COMPANY (US) | 1988-03-22 | — | — | US | disclosed |
| US-4732970-A | Antitumor amino acid and peptide derivatives of 1,4-bis(aminoalkyl and hydroxy-aminoalkyl)amino)-5,8-dihydroxyanthraquinones | AMERICAN CYANAMID COMPANY (US) | 1988-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (25 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10279044-B2 | Bone fracture repair by targeting of agents that promote bone healing | CTSK, CTSG, MMP13 | CASP3 198/4885MDM4 3003/4885TP53 2314/4885 |
| US-20200407394-A1 | THERAPEUTIC AGENT FOR GLYCOGEN STORAGE DISEASE TYPE IA | G6PC1, GAA, GBA3 | CASP3 4124/4885MDM4 4322/4885TP53 1838/4885 |
| US-20180147286-A1 | BONE FRACTURE REPAIR BY TARGETING OF AGENTS THAT PROMOTE BONE HEALING | CTSK, CTSG, MMP13 | CASP3 198/4885MDM4 3003/4885TP53 2314/4885 |
| US-20120294924-A1 | Peptide-Lipid Conjugates And Uses Thereof | VIP, LNPEP, NGLY1 | CASP3 1709/4885MDM4 3874/4885TP53 3455/4885 |
| US-20170028075-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | PAM, UACA, FLT1 | CASP3 1763/4885MDM4 3299/4885TP53 2320/4885 |
| US-10744203-B2 | Bone fracture repair by targeting of agents that promote bone healing | CTSK, CTSG, MMP13 | CASP3 198/4885MDM4 3003/4885TP53 2314/4885 |
| US-20070142324-A1 | Amphiphilic cyclodextrin derivatives, method for preparation thereof and uses thereof | CLTA, PDIA5, ABCC5 | CASP3 3956/4885MDM4 1751/4885TP53 2980/4885 |
| US-20130197205-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | ITGB1, ITGA4, ITGA1 | CASP3 1479/4885MDM4 4598/4885TP53 4326/4885 |
| US-20190160172-A1 | BONE FRACTURE REPAIR BY TARGETING OF AGENTS THAT PROMOTE BONE HEALING | CTSK, CTSG, MMP13 | CASP3 198/4885MDM4 3003/4885TP53 2314/4885 |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | MCL1, ABL1, FLT3 | CASP3 37/4885MDM4 515/4885TP53 28/4885 |
| US-20150038523-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3 | ITGB3, ITGAV, ITGB1 | CASP3 1632/4885MDM4 4647/4885TP53 2850/4885 |
| US-11623009-B2 | Bone fracture repair by targeting of agents that promote bone healing | CTSK, CTSG, MMP13 | CASP3 198/4885MDM4 3003/4885TP53 2314/4885 |
| US-20110073977-A1 | AMINO ACID GENERATOR AND POLYSILOXANE COMPOSITION CONTAINING THE SAME | DAO, BCAT1, BCAT2 | CASP3 3774/4885MDM4 1211/4885TP53 1965/4885 |
| US-20200071275-A1 | ISOQUINOLINE-STEROID CONJUGATES AND USES THEREOF | GRK1, TNK2, CYP11B2 | CASP3 2936/4885MDM4 4634/4885TP53 3556/4885 |
| US-20100063013-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | CTSS, CTSB, CTSZ | CASP3 388/4885MDM4 4847/4885TP53 3573/4885 |
| US-11059789-B2 | Isoquinoline-steroid conjugates and uses thereof | GRK1, TNK2, CYP11B2 | CASP3 2936/4885MDM4 4634/4885TP53 3556/4885 |
| US-20210000962-A1 | BONE FRACTURE REPAIR BY TARGETING OF AGENTS THAT PROMOTE BONE HEALING | CTSK, CTSG, MMP13 | CASP3 198/4885MDM4 3003/4885TP53 2314/4885 |
| US-11958878-B2 | Therapeutic agent for glycogen storage disease type IA | G6PC1, GAA, GBA3 | CASP3 3522/4885MDM4 4263/4885TP53 1614/4885 |
| US-20150150885-A1 | Compositions and Methods for Treating Neoplasia, Inflammatory Disease and Other Disorders | BRPF3, EP300, BRD3 | CASP3 2204/4885MDM4 647/4885TP53 49/4885 |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | CASP3 2783/4885MDM4 1648/4885TP53 614/4885 |
| US-20130136697-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | UACA, PAM, JAK3 | CASP3 1280/4885MDM4 3016/4885TP53 3102/4885 |
| US-11446238-B2 | Injectable dendrimer hydrogel nanoparticles | PAM, UACA, FLT1 | CASP3 1763/4885MDM4 3299/4885TP53 2320/4885 |
| US-20160151508-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | CASP3 3585/4885MDM4 3033/4885TP53 482/4885 |
| US-20010038824-A1 | Intranasal cyclic peptide formulations | VIP, NPPA, SSTR5 | CASP3 2874/4885MDM4 3435/4885TP53 1244/4885 |
| US-20030055213-A1 | Endothelin-antagonizing peptide | NPY1R, ECE1, EDNRB | CASP3 1127/4885MDM4 4129/4885TP53 4032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.